KO Cancer Act

Bill: 118-hr-6807
Sponsor: full_name: Rep. Fitzpatrick, Brian K. [R-PA-1]
Introduced: 2023-12-14
Policy area: Health
Subjects: Appropriations

Cancer

Congressional oversight

Drug therapy

Government studies and investigations

Medical research

Prescription drugs

Research administration and funding
Latest action: action_date: 2023-12-15
text: Referred to the Subcommittee on Health.

Summaries:

tv_txt: I 118th CONGRESS 1st Session H. R. 6807 IN THE HOUSE OF REPRESENTATIVES December 14, 2023 Mr. Fitzpatrick (for himself and Mrs. Dingell ) introduced the following bill; which was referred to the Committee on Appropriations , and in addition to the Committee on Energy and Commerce , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To increase funding for cancer research by the National Cancer Institute to be more in proportion to the mortality rates of cancer.

1. Short title This Act may be cited as the Knock Out Cancer Act or the KO Cancer Act . 2. Increasing NCI budget for cancer research To conduct or support cancer research, there is hereby appropriated, for each of fiscal years 2024 through 2028, to the National Cancer Institute, out of amounts in the Treasury not otherwise appropriated, an amount that is equal to 25 percent of the total amount appropriated to the National Cancer Institute for fiscal year 2022, to remain available until expended. Amounts appropriated pursuant to the preceding sentence shall be in addition to amounts otherwise made available to the National Cancer Institute. 3. Report to Congress on cancer drug shortages (a) Study The Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, in collaboration with such other agencies as the Secretary deems necessary, shall study the reasons for cancer drug shortages, including— (1) economic reasons; (2) supply chain failures; (3) delays and other complications relating to— (A) the development of cancer drugs; and (B) the approval of such drugs by the Food and Drug Administration; and (4) insufficient generic drugs and biosimilar biological products. (b) Report (1) In general Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall complete the study under subsection (a) and submit a report to the appropriate committees of the Congress on the results of such study. (2) Recommendations The report under paragraph (1) shall include recommendations for addressing the reasons for cancer drug shortages.